跳至主要内容
临床试验/ITMCTR2100005293
ITMCTR2100005293招募中未知

Objective to evaluate the clinical effect of tongnaoyin on the establishment of collateral circulation in patients with acute cerebral infarction by multi-mode CT imaging technology

Jiangsu Province Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1.Age: 18-75 years old (including 18 and 75), regardless of gender;
  • 2.Patients who were diagnosed as ischemic stroke (in accordance with the diagnostic criteria of ischemic stroke in the Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018) underwent CT/MRI examination to exclude cerebral hemorrhage;
  • 3.Patients within 7 days of onset;
  • 4.Patients with first onset or good prognosis after the last onset (MRS score 0-1) and relapse;
  • 5.NIHSS score >= 4 and <= 22;
  • 6.Informed consent of patients or their family members to the study and signed the informed consent form.

排除标准

  • 1.History of cerebral hemorrhage or hemorrhagic cerebrovascular disease (including subarachnoid hemorrhage, cerebral hemorrhage and other intracranial hemorrhage confirmed by head CT / MRI) in the past six months;
  • 2.The MRS score of patients with recurrent cerebral infarction was more than 1 before the onset;
  • 3.It was confirmed by examination that cerebral embolism was caused by detachment of mural thrombus of brain tumor, brain trauma, brain parasitic disease, metabolic disorder, rheumatic heart disease, coronary heart disease and other heart diseases complicated with atrial fibrillation and other patients with unknown reasons;
  • 4.Patients with other diseases affecting limb function, such as lameness, osteoarthritis (active stage), rheumatoid arthritis (active stage), gouty arthritis, etc., may affect neurological or functional examination;
  • 5.Diabetic complications (such as severe diabetic nephropathy leading to renal insufficiency, diabetic peripheral neuropathy affecting motor function evaluator, diabetic ketoacidosis, etc.) and recurrent hypoglycemia patients;
  • 6.The patients with severe malnutrition, severe blood diseases (such as hypoproteinemia, severe anemia, etc.) and severe electrolyte disorder which can not be corrected after treatment;
  • 7.The patients with severe heart and lung diseases and chronic liver and kidney dysfunction had ALT and AST > 1.5 times of the normal upper limit and Renal function impairing creatinine (Cr) > the normal upper limit;
  • 8.Women preparing for pregnancy, pregnancy or lactation;
  • 9.Disabled patients (blindness, deafness, mute, mental retardation, mental retardation, physical disability) stipulated by law;
  • 10.Known to be allergic to the components of the drug and allergic constitution;
  • 11.The researcher thinks that it is not suitable for the patient to participate in this clinical research;
  • 12.Patients who participated in other clinical trials within 3 months.

研究者

相似试验